APVO - Aptevo Therapeutics GAAP EPS of $5.58 August, 11 2022 08:48 AM Aptevo Therapeutics Inc. Aptevo Therapeutics press release ( NASDAQ: APVO ): Q2 GAAP EPS of $5.58. Aptevo had cash, cash equivalents and restricted cash of $30 million as of June 30, 2022. For further details see: Aptevo Therapeutics GAAP EPS of $5.58